Veru (VERU) Other Non-Current Assets (2010 - 2026)
Veru (VERU) posted quarterly Other Non-Current Assets of $60549.0 for Q1 2026, down 93.5% quarter-over-quarter from $930847.0 in Q4 2025.
Veru (VERU) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Other Non-Current Assets for 17 consecutive years, with $60549.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $60549.0; the TTM figure through Mar 2026 stood at $60549.0 (changed N/A YoY), while the FY2025 annual figure was $930847.0, down 89.37% from the prior year.
- Other Non-Current Assets declined to $60549.0 in Q1 2026 per VERU's latest filing, from $930847.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $8.8 million in Q3 2024 and bottomed at $60549.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $1.8 million across 5 years, with a median of $1.3 million in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 479.16% — and 2025, when it tumbled 89.37%.
- Veru's Other Non-Current Assets stood at $856435.0 in 2022, then jumped by 54.37% to $1.3 million in 2023, then fell by 25.15% to $989596.0 in 2024, then decreased by 5.94% to $930847.0 in 2025, then plunged by 93.5% to $60549.0 in 2026.
- Business Quant data shows VERU's Other Non-Current Assets at $60549.0 in Q1 2026, $930847.0 in Q4 2025, and $930847.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 297,998.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 297,998.00 |
| Mar 31, 2026 | 60,549.00 |
| Dec 31, 2025 | 930,847.00 |
| Sep 30, 2025 | 930,847.00 |
| Dec 31, 2024 | 989,596.00 |
| Sep 30, 2024 | 8.76 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 778,697.00 |
| Dec 31, 2022 | 856,435.00 |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 2.28 Mn |
| Mar 31, 2022 | 2.29 Mn |
| Dec 31, 2021 | 878,417.00 |
| Sep 30, 2021 | 878,502.00 |
| Jun 30, 2021 | 880,888.00 |
| Mar 31, 2021 | 762,746.00 |